MK-8457 / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-8457 / Merck (MSD)
NCT01651936 / 2012-002181-12: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)

Terminated
2a
56
NA
MK-8457 100 mg, Methotrexate, Rheumatrex, Trexall, Dose-match placebo
Merck Sharp & Dohme LLC
Rheumatoid Arthritis
10/13
10/13
ACTRN12612000774820: A Rheumatoid Arthritis Study to Test the Safety, Tolerability, and Efficacy of MK-8457 in Patients with an Inadequate Response or Intolerance to Anti-TNF-alpha Therapy

Terminated
2
178
 
MSD - Merck Sharp & Dohme (Australia) Pty Limited, MSD - Merck Sharp & Dohme (Australia) Pty Limited
Rheumatoid Arthritis
 
 
NCT01569152 / 2012-000439-17: Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

Terminated
2
82
NA
MK-8457 100 mg, Dose-Matched Placebo, Methotrexate, MTX
Merck Sharp & Dohme LLC
Rheumatoid Arthritis (RA)
10/13
10/13

Download Options